These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 3008128)

  • 21. [Antisecretory effect of losec and pariet in peptic ulcer therapy].
    Nemytin IuV; Makarov IuS; Pavlov AI; Kashchenko OI; Lezhenina NP; Golochalova TV
    Voen Med Zh; 2002 Oct; 323(10):44-6. PubMed ID: 12479006
    [No Abstract]   [Full Text] [Related]  

  • 22. [Losek (omeprazole), a new therapeutic agent in the treatment of peptic ulcer and hyperacidity states].
    Bulgakov SA
    Klin Med (Mosk); 1995; 73(5):11-6. PubMed ID: 8815266
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of ulcer disease.
    Spenney JG
    Ala J Med Sci; 1985 Jan; 22(1):49-53. PubMed ID: 3883827
    [No Abstract]   [Full Text] [Related]  

  • 24. Relationship of omeprazole-induced hypergastrinemia to gastric pH.
    Larson GM; Sullivan HW; Rayford PL
    Surgery; 1986 Aug; 100(2):175-80. PubMed ID: 3738749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Omeprazole in the Zollinger-Ellison syndrome.
    Bardram L; Stadil F
    Scand J Gastroenterol; 1986 Apr; 21(3):374-8. PubMed ID: 3715402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Substituted benzimidazole, inhibiting substance of K+/H+ ATPase of parietal cells--a new principle in the treatment of peptic ulcer].
    Sewing KF
    Internist (Berl); 1983 Dec; 24(12):680-3. PubMed ID: 6319314
    [No Abstract]   [Full Text] [Related]  

  • 27. Medical treatment of peptic ulcers.
    Deveney CW; Deveney KE
    Surg Annu; 1985; 17():219-33. PubMed ID: 3883541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug therapy of peptic ulcer disease.
    Ching CK; Lam SK
    Br J Hosp Med; 1995 Jul 12-Aug 15; 54(2-3):101-6. PubMed ID: 7551483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Indications and use of omeprazole in esophago-gastro-duodenal diseases].
    Martín de Argila C; Boixeda de Miquel D; Moreira Vicente V; García Plaza A
    Rev Clin Esp; 1999 Nov; 199(11):729-39. PubMed ID: 10638238
    [No Abstract]   [Full Text] [Related]  

  • 30. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas.
    Jensen RT
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):4-19. PubMed ID: 16433886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omeprazole: effective, convenient therapy for Zollinger-Ellison syndrome.
    McArthur KE; Collen MJ; Maton PN; Cherner JA; Howard JM; Ciarleglio CA; Cornelius MJ; Jensen RT; Gardner JD
    Gastroenterology; 1985 Apr; 88(4):939-44. PubMed ID: 3972233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Proton pump inhibitors: Tenatoprazole (TU-199)].
    Nakamura T
    Nihon Rinsho; 2002 Feb; 60 Suppl 2():650-4. PubMed ID: 11979864
    [No Abstract]   [Full Text] [Related]  

  • 33. L-type amino acids stimulate gastric acid secretion by activation of the calcium-sensing receptor in parietal cells.
    Busque SM; Kerstetter JE; Geibel JP; Insogna K
    Am J Physiol Gastrointest Liver Physiol; 2005 Oct; 289(4):G664-9. PubMed ID: 15961860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Lansoprazol ++ : a new proton pump inhibitor].
    Baczek J; Laskowiec G
    Pol Merkur Lekarski; 1998 Jun; 4(24):339-41. PubMed ID: 9771021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lansoprazole: a comprehensive review.
    Zimmermann AE; Katona BG
    Pharmacotherapy; 1997; 17(2):308-26. PubMed ID: 9085323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Helicobacter pylori increases the antisecretory activity of omeprazole in the parietal cell and the proton pump].
    De Korwin JD
    Gastroenterol Clin Biol; 2001 Dec; 25(12):1127-8. PubMed ID: 11911004
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacological regulation of gastric acid secretion in the apical membrane of parietal cells; a new target for antisecretory drugs.
    Okabe S; Shimosako K; Amagase K
    J Physiol Pharmacol; 2001 Dec; 52(4 Pt 1):639-56. PubMed ID: 11787764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease.
    Naesdal J; Bodemar G; Walan A
    Scand J Gastroenterol; 1984 Oct; 19(7):916-22. PubMed ID: 6531660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review article: the clinical pharmacology of proton pump inhibitors.
    Sachs G; Shin JM; Howden CW
    Aliment Pharmacol Ther; 2006 Jun; 23 Suppl 2():2-8. PubMed ID: 16700898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging strategies in ulcer therapy: pumps and receptors.
    Berglindh T; Sachs G
    Scand J Gastroenterol Suppl; 1985; 108():7-14. PubMed ID: 2988110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.